Financial Performance - Revenue for the nine months ended September 30, 2022, was RMB 689,399,000, an increase of 15.5% compared to RMB 596,776,000 for the same period in 2021[12]. - Gross profit for the nine months ended September 30, 2022, was RMB 304,560,000, representing a 10.6% increase from RMB 275,364,000 in the previous year[12]. - Profit from operations for the nine months ended September 30, 2022, was RMB 51,909,000, up 41.7% from RMB 36,634,000 in 2021[12]. - Profit before taxation for the nine months ended September 30, 2022, was RMB 47,335,000, an increase of 37.3% compared to RMB 34,441,000 in the same period of 2021[14]. - Net profit attributable to owners of the Company for the nine months ended September 30, 2022, was RMB 35,886,000, a rise of 42.5% from RMB 25,207,000 in 2021[14]. - Earnings per share for the nine months ended September 30, 2022, was RMB 2.14 cents, compared to RMB 1.50 cents for the same period in 2021[14]. - The Company reported a total comprehensive income of RMB 34,209,000 for the nine months ended September 30, 2022, compared to RMB 26,661,000 in 2021, marking a 28.3% increase[14]. - The profit and total comprehensive income for the period ended September 30, 2022, was RMB 34,209,000, compared to RMB 25,207,000 for the same period in 2021, indicating a year-over-year increase of approximately 35.7%[17]. - For the three months ended September 30, 2022, total revenue was RMB 250,530,000, an increase of 21.8% compared to RMB 205,582,000 for the same period in 2021[33]. - For the three-month period ended September 30, 2022, the profit attributable to owners of the Company was approximately RMB 15,542,000, representing an increase of 179% compared to RMB 5,560,000 for the same period in 2021[50]. - For the nine-month period ended September 30, 2022, the profit attributable to owners of the Company was approximately RMB 35,886,000, an increase of 42.5% from RMB 25,207,000 for the same period in 2021[50]. Expenses and Costs - Selling and distribution expenses for the nine months ended September 30, 2022, were RMB 174,350,000, a decrease of 3.2% from RMB 180,138,000 in 2021[12]. - Administrative expenses for the nine months ended September 30, 2022, increased to RMB 64,360,000 from RMB 55,949,000 in 2021, reflecting a rise of 15.1%[12]. - Other operating expenses amounted to approximately RMB 31,766,000, an increase of approximately 21.53% from RMB 26,139,000 for the corresponding period of last year[82]. - Finance costs increased by approximately 108.57% to approximately RMB 4,574,000 from RMB 2,193,000 for the corresponding period of last year[83]. - Staff costs for the three months ended September 30, 2022, increased to RMB 35,712,000, a rise of 37.7% compared to RMB 25,940,000 in the same period of 2021[39]. - Research and development costs for the three months ended September 30, 2022, were RMB 7,831,000, an increase of 16.9% from RMB 6,699,000 in 2021[42]. Equity and Assets - As of September 30, 2022, the total equity of the company was RMB 975,682,000, an increase from RMB 942,867,000 as of September 30, 2021, reflecting a growth of approximately 3.5% year-over-year[17]. - The retained earnings as of September 30, 2022, were RMB 282,071,000, up from RMB 236,109,000 as of September 30, 2021, representing a growth of about 19.5%[17]. - The company completed the acquisition of a subsidiary, which resulted in a decrease of RMB 13,126,000 in equity[17]. - The total assets of the company as of September 30, 2022, were not explicitly stated but can be inferred from the total equity and liabilities[17]. Revenue Segmentation - Revenue from manufacturing and selling medicines was RMB 174,975,000 for the three months ended September 30, 2022, up from RMB 130,547,000 in the same period of 2021, representing a growth of 34.0%[33]. - Revenue from sales and distribution of medicines and healthcare products reached RMB 75,555,000 for the three months ended September 30, 2022, slightly up from RMB 75,035,000 in the same period of 2021[33]. - Revenue from the manufacturing and selling of medicines segment increased by approximately 33.17%, amounting to approximately RMB 485,157,000, which is about 70.37% of the Group's total revenue[74]. - Revenue from the sales and distribution of medicines and healthcare products segment decreased by approximately 12.14%, totaling approximately RMB 204,242,000, which is about 29.63% of the Group's total revenue[74]. Corporate Governance and Compliance - The Company has adopted a code of conduct regarding securities transactions by Directors, confirming compliance by all Directors during the Reporting Period[135]. - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[139]. - The Company is in the process of identifying a suitable candidate to fill the vacancy of the General Manager[140]. - The Board will continue to enhance the standard of corporate governance to ensure responsible business operations[146]. - Neptunus Bio-engineering confirmed compliance with the Non-Competition Undertakings during the Reporting Period[131]. Research and Development - The Group's research and development efforts have resulted in 22 patents for invention, with 4 products having passed the quality consistency evaluation for generic drugs[61]. - The evaluation of Doxofylline Injection has been approved, and the Concentrated Sodium Potassium Magnesium Calcium Injection is pending approval[61]. Shareholding Structure - The controlling shareholder, Neptunus Bio-engineering, held approximately 73.51% of the entire issued share capital of the company, with 70.38% directly held and 3.13% indirectly held[93]. - As of September 30, 2022, Neptunus Bio-engineering holds 1,181,000,000 domestic shares, representing approximately 94.33% of the company's issued share capital[111]. - Neptunus Group is deemed to be interested in 1,233,464,500 domestic shares, which accounts for approximately 98.52% of the company's issued share capital[113]. - The company has not adopted any share option scheme or granted any options, convertible securities, or warrants as of September 30, 2022[111].
海王英特龙(08329) - 2022 Q3 - 季度财报